Investigating BCLW's role in lymphoma survival and treatment resistance
BCLW in lymphoma survival and resistance to targeted BCL2 family therapies
This study is looking at how a protein called BCLW helps certain types of B cell lymphomas survive and resist treatments, with the goal of finding new ways to help patients whose current therapies aren't working.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10992673 on NIH RePORTER |
What this research studies
This research focuses on understanding how BCLW, an anti-apoptotic protein, contributes to the survival of B cell lymphomas and their resistance to targeted therapies. The study aims to explore the mechanisms by which BCLW protects cancer cells from apoptosis, particularly in cases where traditional treatments like venetoclax have failed. By analyzing the expression levels of BCLW in various lymphoma types, the research seeks to identify potential new therapeutic targets for improving patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with B cell lymphomas, particularly those with high levels of BCL2 and BCLW expression.
Not a fit: Patients with lymphomas that do not exhibit high levels of BCLW or BCL2 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with B cell lymphomas that currently do not respond well to existing therapies.
How similar studies have performed: While the role of BCLW in lymphomas is relatively novel, previous studies have shown success in targeting other BCL2 family members, indicating potential for breakthroughs in this area.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Eischen, Christine M. — Thomas Jefferson University
- Study coordinator: Eischen, Christine M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.